The therapeutic efficacy of CAR<sup>TM4SF1</sup>-EVs is primarily attributed to their ability to remodel the immunosuppressive tumor microenvironment (TME), notably by enhancing CD8+ T cell activity and eliciting robust antitumor immune responses. This evidence concerns the gene CD8A and neoplasm.